share_log

iBio Inc | CORRESP: CORRESP

iBio Inc | CORRESP: CORRESP

iBio Inc | CORRESP:信函
美股SEC公告 ·  2024/07/26 01:05

Moomoo AI 已提取核心信息

iBio Inc, a biotechnology company, has submitted an amendment to its Registration Statement on Form S-3 in response to comments from the staff of the Securities and Exchange Commission (SEC). The SEC's comments, dated July 3, 2024, addressed concerns regarding the company's Prospectus Summary Overview. Specifically, the SEC requested that iBio Inc provide a more balanced discussion of its platform and AI-engine, including the company's limited operating history, lack of clinical trials for product candidates, and the risks associated with developing and commercializing its products. iBio Inc has updated its Prospectus Summary to reflect these concerns and has also revised its disclosure to substantiate performance and leadership claims about its patented AI-engine and technologies. The amendment was filed concurrently with the response to the SEC's comments on July 25, 2024.
iBio Inc, a biotechnology company, has submitted an amendment to its Registration Statement on Form S-3 in response to comments from the staff of the Securities and Exchange Commission (SEC). The SEC's comments, dated July 3, 2024, addressed concerns regarding the company's Prospectus Summary Overview. Specifically, the SEC requested that iBio Inc provide a more balanced discussion of its platform and AI-engine, including the company's limited operating history, lack of clinical trials for product candidates, and the risks associated with developing and commercializing its products. iBio Inc has updated its Prospectus Summary to reflect these concerns and has also revised its disclosure to substantiate performance and leadership claims about its patented AI-engine and technologies. The amendment was filed concurrently with the response to the SEC's comments on July 25, 2024.
生物技术公司ibio inc已根据美国证券交易委员会(SEC)的工作人员意见提交了关于其S-3表格的修订案。SEC于2024年7月3日发表的意见涉及关于公司的招股简介概述的问题。具体而言,SEC要求ibio inc提供有关其平台和人工智能引擎的更加客观的讨论,包括公司有限的运营历史、产品候选者缺乏临床试验以及开发和商业化产品所面临的风险。ibio inc已更新其招股简介以反映这些问题,并对其专利人工智能引擎和技术方面的性能和领导力声明进行了修订,以提供支持。修订案于2024年7月25日同时提交给SEC作为对其意见的回应。
生物技术公司ibio inc已根据美国证券交易委员会(SEC)的工作人员意见提交了关于其S-3表格的修订案。SEC于2024年7月3日发表的意见涉及关于公司的招股简介概述的问题。具体而言,SEC要求ibio inc提供有关其平台和人工智能引擎的更加客观的讨论,包括公司有限的运营历史、产品候选者缺乏临床试验以及开发和商业化产品所面临的风险。ibio inc已更新其招股简介以反映这些问题,并对其专利人工智能引擎和技术方面的性能和领导力声明进行了修订,以提供支持。修订案于2024年7月25日同时提交给SEC作为对其意见的回应。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息